Press Release

Han Kun is pleased to welcome to the firm Mr. Aaron Gu, a legal expert in the life sciences and healthcare sector. Mr. Gu has for years been committed to advising market participants in the life sciences, biopharmaceutical, medical and healthcare industries, and is well-experienced in these fields. Mr. Gu will be primarily based in Han Kun's Shanghai office.

Mr. Gu focuses on corporate, regulatory compliance and transactional services for the life sciences, biopharmaceutical, medical, and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities. Specifically, Mr. Gu covers a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review".

Prior to joining Han Kun, Mr. Gu practiced law with Covington & Burling LLP in Shanghai, Washington D.C., and New York for approximately 8 years.

Han Kun has a dedicated life sciences and healthcare team, and has been consistently ranked as a leading law firm in the life sciences and healthcare sector by authoritative legal directories, including Chambers and Partners, The Legal 500, Asialaw Profiles, and China Business Law Journal. The firm is committed to providing clients in the life sciences and healthcare industries with comprehensive legal services, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital markets, pharmaceutical license in/out and asset sale/purchase transactions, intellectual property, compliance and regulatory, data protection, and dispute resolution. The addition of Mr. Gu to Han Kun will further bolster the firm's service capabilities in the life sciences and healthcare sector.